Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Loos

Showing results (171-180 of 215) with videos related to

Pageof 22
Sort By:
Anti-Cancer Drugs|August 7, 2001
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9J H Schellens, P Dombernowsky, J Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Cancer Chemotherapy and Pharmacology|August 4, 2010
Effects of methimazole on the elimination of irinotecanJessica M van der Bol, Theo J Visser, Walter J Loos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecanJessica M van der Bol, Ron H J Mathijssen, Geert-Jan M Creemers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effectsM J de Jonge, W J Loos, H Gelderblom, et al.
Anti-Cancer Drugs|November 26, 1999
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoproteinA Sparreboom, A S Planting, R C Jewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)C J Gerrits, J H Schellens, H Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction studyJessica M van der Bol, Walter J Loos, Floris A de Jong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapyAnne-Joy M de Graan, Walter J Loos, Lena E Friberg, et al.
Pageof 22

Showing results (171-180 of 215) with videos related to

Sort By:
Pageof 22
Anti-Cancer Drugs|August 7, 2001
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9J H Schellens, P Dombernowsky, J Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Cancer Chemotherapy and Pharmacology|August 4, 2010
Effects of methimazole on the elimination of irinotecanJessica M van der Bol, Theo J Visser, Walter J Loos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecanJessica M van der Bol, Ron H J Mathijssen, Geert-Jan M Creemers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effectsM J de Jonge, W J Loos, H Gelderblom, et al.
Anti-Cancer Drugs|November 26, 1999
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoproteinA Sparreboom, A S Planting, R C Jewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)C J Gerrits, J H Schellens, H Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction studyJessica M van der Bol, Walter J Loos, Floris A de Jong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapyAnne-Joy M de Graan, Walter J Loos, Lena E Friberg, et al.
Pageof 22